Welcome to our dedicated page for Cryo-Cell Intl SEC filings (Ticker: CCEL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Cryo-Cell International filings document material events, governance matters, financing arrangements and exchange-listing compliance for a cord blood banking and cryogenic storage company. Recent 8-K reports cover NYSE American continued-listing standards, dividend determinations, annual meeting timing, and Regulation FD disclosures tied to company announcements.
The filing record also includes definitive proxy materials for director elections, auditor ratification, executive compensation voting and stockholder meeting procedures. Financing disclosures describe amendments to the company’s Susser Bank credit agreement, including revolving credit and term loan arrangements, subsidiary guarantor provisions involving Celle Corp., maturity terms, interest-rate mechanics and related security documents.
David Portnoy, Chairman and Co-CEO of Cryo-Cell International, Inc. (CCEL), reported multiple open-market purchases of the company's common stock on September 16-18, 2025. He acquired 6,449 shares on 09/16/2025 at a weighted average price of $4.46, 5,564 shares on 09/17/2025 at $4.43, and 3,411 plus 1,751 shares on 09/18/2025 at weighted averages around $4.46 and $4.49 respectively. After these transactions his reported direct beneficial ownership in common stock reached 827,344 shares, and he also reports additional indirect holdings
David Portnoy, Chairman and Co-CEO of Cryo-Cell International, Inc. (CCEL), reported multiple open-market purchases of the company's common stock on September 16-18, 2025. He acquired 6,449 shares on 09/16/2025 at a weighted average price of $4.46, 5,564 shares on 09/17/2025 at $4.43, and 3,411 plus 1,751 shares on 09/18/2025 at weighted averages around $4.46 and $4.49 respectively. After these transactions his reported direct beneficial ownership in common stock reached 827,344 shares, and he also reports additional indirect holdings
Insider purchases by Cryo-Cell International director and 10% owner David Portnoy are reported across September 8-10, 2025. The Form 4 shows multiple open-market purchases of Common Stock at prices between $4.30 and $4.49, including a 5,271-share purchase at a weighted average $4.31 on 09/08/2025 and a series of purchases on 09/09-09/10/2025. The listed transactions total 42,900 shares acquired during the reported dates, and the filing details existing indirect holdings and option positions, including several outstanding stock options covering 529,879 shares in the aggregate. The report is signed by David Portnoy.
Cryo-Cell International, Inc. has scheduled its 2025 Annual Meeting of Stockholders for October 21, 2025. The company set September 15, 2025 as the record date, which means only stockholders of record on that date will be entitled to receive notice of and vote at the meeting.
Stockholders who want to present business or nominate directors at the Annual Meeting must deliver the required notice under the Company’s Bylaws no later than the 10th calendar day after public disclosure of the meeting date, which occurred on September 10, 2025.
David Portnoy, Chairman and Co-CEO of Cryo-Cell International, filed a Form 4 reporting insider changes on 09/02/2025. The filing discloses a disposition of 15,611 shares of common stock on that date at an effective price of $0.00. The explanation states the child reached majority and the reporting person no longer has beneficial ownership of those shares.
The filing also lists the reporting person’s existing beneficial holdings and derivative positions. Non-derivative holdings are shown across multiple accounts and entities (including direct holdings and interests through retirement accounts, family members, and affiliated entities). Reported stock options total significant positions including 280,000 options at $12.27 (expiring 12/22/2028) and multiple tranches of 50,000 options at various strike prices and expirations.
David I. Portnoy, Chairman and Co-CEO of Cryo-Cell International, Inc. (CCEL), reported multiple open-market purchases of the company’s common stock and discloses outstanding stock options. Between 08/25/2025 and 08/27/2025 Portnoy purchased several lots through retirement accounts, including 4,500 shares at a weighted average $4.65, 5,000 shares at $4.65, 11,101 shares at $4.44, 7,860 shares at $4.42, 4,500 shares at a weighted $4.53, and 6,218 shares at $4.44. The Form 4 lists numerous indirect holdings (by 401k, IRA, spouse, LLCs and corporations) and multiple outstanding stock options with exercise prices ranging from $4.30 to $12.27 covering named share amounts up to 280,000 shares for the $12.27 option.
Cryo-Cell International’s Chairman, Co-CEO and 10% owner David Portnoy reported indirect open-market purchases totaling 19,301 shares of common stock. The buys, made through retirement and similar accounts on August 15, 18 and 19, 2025, were executed at weighted-average prices ranging from about $4.23 to $4.50 per share.
PORTNOY DAVID reported open-market purchase transactions in a Form 4 filing for CCEL. The filing lists transactions totaling 5,826 shares at a weighted average price of $4.17 per share. Following the reported transactions, holdings were 122,838 shares.